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Objective. To assess the short-term eﬃcacy and safety of two kinds of Traditional Chinese herbal patches, Fufang Nanxing Zhitong
Gao (FNZG) and Shangshi Jietong Gao (SJG), for painful knee osteoarthritis (OA). Methods. Patients were randomly enrolled in
a double-blind, placebo-controlled study to receive FNZG (n = 60), SJG (n = 60), or placebo patch (n = 30) for 7 days. Outcome
measures included visual analogue scale (VAS), Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), and
Traditional Chinese Medicine Syndrome Questionnaire (TCMSQ) subscale. Results. Although there was no signiﬁcant diﬀerence
among, three groups in short-term pain management, patients receiving FNZG got signiﬁcant improvement in symptom of fear
of coldness as compared with placebo patch (P = 0.029). The most common local adverse events of rash, itching, erythema, and
slightly damaged skin were observed in 7% of participants. Conclusions.F N Z Gm a yb eau s e f u lt r e a t m e n tf o rs ym p t o mo fk n e eO A
and merits long-term study in broader populations.
1.Introduction
Osteoarthritis (OA) of the knee increases in prevalence with
age and is a major cause of pain, locomotor disability world-
wide [1, 2]. OA is characterized by a series of pathological
changes in the whole joint, including articular cartilage
degeneration and destruction, subchondral sclerosis, syn-
ovial hyperplasia, joint capsule contracture, ligament laxity
or contracture, and muscles weakness and atrophy [1, 3].
The main factors consistently associated with knee OA were
obesity, prior knee injuries, female, gender and older age
[1, 3]. Until now, no ideal disease modifying medications
exist in short-term pain management of knee OA.
Patients with knee OA usually call for a better pain con-
trolandlessadverseevents(AEs)withinashort-termperiod.
Therefore, as aging and comorbidities increase, a more con-
venient approach is eagerly to be applied. In China and
increasingly worldwide, among pharmacological therapies,
the recent guidelines recommended topical medications as
an alternative or adjunctive therapy, or even as ﬁrst-line
therapy for knee OA [2–4]. Before oral administration,
topical treatments are usually recommended to relieve mild
or moderate pain of knee OA, because its safety proﬁle is
fairly well [3].
A great number of Chinese doctors have prescribed some
forms of Traditional Chinese Medicine (TCM) to patients
with knee OA, of which the herbal patch is a common
approach and has long been a standard treatment [3, 4].
The patch, called “Bo Tie” in ancient times, is a unique
topical formulation of TCM, which is made through frying
edible vegetable oil and the herbs, discarding the residue,
then mixing with Componere Hydrargyrum (Shenyao) and
cooling,andcoatingwithclothorpaperﬁnally.Whenaﬃxed
to the injured area or acupoint, it could alleviate symptoms
in a certain part of body, such as bruises or muscle pain [5].2 Evidence-Based Complementary and Alternative Medicine
The herbalpatch is usedundertheprinciple ofsyndrome
diﬀerentiation based on TCM theory. OA is known as the
bone obstruction disease, which means either the limbs or
the joints suﬀer from pain, stiﬀness, and/or malfunction
due to invasions of wind cold or dampness into knees
accompanied by the disharmony of Qi and blood, conse-
quently leading to the syndrome of “cold dampness” and
“blood stasis” [6]. Accordingly, diﬀerent herbal formulations
were prepared for diﬀerent symptoms due to cold evil and
dampness evil.
Currently, Fufang Nanxing Zhitong Gao (FNZG) and
Shangshi Jietong Gao (SJG) are two most prescribed herbal
patches in China with the indication for the management
of painful knee OA. Published literatures documented that
FNZG or SJG had a better eﬃcacy for knee OA or joint pain
[7–13]. However, these interventions have, to date, not been
rigorously evaluated, and such methods have been regarded
mostly eﬀective in case reports. Nevertheless, only one article
about randomized controlled trial of FNZG for knee OA was
published, but interpretation of its results was limited by
methodological quality, including restricted demographics
characteristics, absence of standardized outcome measures,
and poor statistical analysis [11]. In addition, some AEs
also have been reported in the literatures [14–17]. Most
critically,althoughTraditionalChineseherbalpatchhasbeen
applied over centuries, there were no placebo-controlled
trials published for validating its eﬀectiveness in treating
knee OA.
Therefore, we conducted a randomized, double-blind,
and placebo-controlled trial to explore the eﬀectiveness and
safety of FNZG and SJG, for the management of painful
knee OA in a short-term design. We hypothesized that at
the end of the 7-day treatment, patients receiving FNZG
or SJG would have greater reduction in pain and better
improvements in symptoms than those in the placebo
control group.
2.MaterialsandMethods
2.1. Study Design. This was a prospective 7-day, 3-arm, and
double-blind study in subjects with painful knee OA which
compared FNZG versus the placebo, and SJG versus the
placebo with imbalanced design, the allocation ratio was 2:
2:1 for FNZG, SJG, and placebo, respectively. The study
was approved by the Ethical Committee of South Hospital,
South Medical University and registered in Clinical Trials
of Chinese Cochrane Center (Registered no. ChiCTR-TRC-
10000963).
2.2. Setting and Participants. The study was conducted in
the outpatient of Shuguang Hospital, a teaching hospital
aﬃliated to Shanghai University of TCM.
Patients with painful knee OA were recruited from
the previous study: discontinue interval [6], clinic patient
database, and the community by batch. Baseline question-
naires were not ﬁlled out until at least 15 participants had
accumulated, and then signed informed consent if eligible.
The eligibility criteria consisted of knee OA diagnostic
criteria of Chinese Orthopaedic Association (COA) [3]a n d
TCMsyndrome[18],maleorfemalebetween40and70years
of age, evidence of idiopathic OA of at least one knee, patient
assessment of OA pain in index knee above 20mm on the
100mm visual analogue scale (VAS) at baseline. Exclusion
criteria included (1) pain greater than 20mm on VAS in the
nonindex knee (either at rest or with movement); (2) prior
injection or arthroscopy of study knee within 3 months; (3)
an injury or surgery to the same body region within the prior
6 months or a lifetime history of 3 or more injuries/surgeries
to the injured body region; (4) signs of clinically important
active inﬂammation of the study knee joint including
redness, warmth, and/or a large, bulging eﬀusion with the
lossofnormalcontouratthescreeningand/orbaselinevisits;
(5) crystalline-induced synovitis (e.g., gout, pseudogout,
nonsteroid arthritis, hydroxyapatite deposit), rheumatoid
arthritis, psoriatic arthritis, septic arthritis, ﬁbromyalgia,
systemic lupus, erythematosus collagen vascular disease;
(6) with severe cardiovascular, lung, liver, kidney, and
hematopoietic system and other serious primary diseases
(such as myocardial infarction, heart failure), cancer, and
neurological joint pain; (7) complications of the disease
aﬀected joints, such as psoriasis, brown yellow disease,
metabolic bone disease, acute trauma; (8) using nonsteroidal
anti-inﬂammatory drugs (NSAIDs) and received glucocorti-
coid treatment within 2 and 4 weeks, respectively; (9) having
experienced a history of skin irritation using patches; (10)
other reasons in the opinion of investigators that the subject
did not suit, for example, participating in other trials.
OAatothersitesbesidesthekneewaspermissible.Incase
of poor quality, repeated images were acquired.
2.3. Interventions. Participants in each arm received FNZG,
SJG, or placebo patch, respectively. All patches had the same
size of 10cm × 13cm and were matched with each other for
taste, color, and package. One kind of patch in 7 days was
packed into a box and labeled patch code in eye-catching
position. Meanwhile, patches were stored, administrated,
and dispensed by a pharmacist in a larger container at the
scientiﬁc research pharmacy.
The FNZG (China State Food and Drug Adminis-
tration (SFDA) approval no. Z10970019, Jiangsu Nanx-
ing Pharmaceutical Co., Ltd.) contained active ingredients
of Hypaconitine (C33H45NO10) and Eugenol (C10H12O2),
which were extracted mainly from raw Rhizoma Arisaematis
(Sheng Tiannanxing), raw Radix Aconiti (Sheng Chuanwu),
and Flos Caryophylli (Dingxiang). In addition, it consisted
of other 9 kinds of herbs: Cortex Cinnamomi (Rougui),
Radix Angelicae Dahuricae (Baizhi), Herba Asari (Xixin),
Rhizoma Chuanxiong (Chuanxiong), Radix Cynanchi Pan-
icuclati (Xuchangqing), processed Olibanum (Zhi Ruxiang),
processed Myrrha (Zhi Moyao), Camphora (Zhangnao), and
Borneolum Syntheticum (Bingpian).
The SJG (SFDA approval no. Z32021099, Changzhou
Shenghui Pharmaceutical Co., Ltd.) contained similar active
ingredients with FNZG. It consisted of 17 kinds of herbs.
Some were same as FNZG, such as raw Rhizoma Arisaematis
(Sheng Tiannanxing), raw Radix Aconiti (Sheng Chuanwu),
Radix Angelicae Dahuricae (Baizhi), Cortex Cinnamomi
(Rougui), Camphora (Zhangnao), Borneolum SyntheticumEvidence-Based Complementary and Alternative Medicine 3
Table 1: Subscale of investigator assessment of knee OA condition measured by Traditional Chinese Medicine Syndrome Questionnaire
(TCMSQ).
Items
Assessment criteria
0 point 2 points 4 points 6 points
Swelling None Suspected ﬂoating
patella test
Positive ﬂoating
patella test Signiﬁcantly
Range of motion Move freely 120◦∼140◦ 100◦∼120◦ <100◦
Fatigue in the region
of waist and knee
muscles
None
Occasionally, but not
aﬀected the life and
work
Occurred only
after working
Persisted during
the life
Fear of coldness None
Not palpable over
knee joints when
palpation
Palpable over
knee joints
when palpation
Obviously,
needed clothing
to protect the
whole body
(Bingpian), but Radix Angelicae Pubescentis (Duhuo), Cor-
tex Acanthopanacis (Wujiapi), Rhizoma Curcuma Longae
(Jianghuang), Flos Carthami (Honghua), Folium Artemisiae
Argyi (Aiye), Rhizoma Atractylodis (Cangzhu), Rhizoma
Pinellia (Banxia), Semen Sinapis (Baijiezi), Semen Vaccariae
(Wangbuliuxing), raw Radix Aconiti Kusnezoﬃi (Sheng
Caowu), and Herba Menthae (Bohe).
The placebo patch (approval no. 1640087, Zhejiang,
Tongxiang, Hongshi Pharmaceutical Co., Ltd.) was acrylic
pressure-sensitive adhesive tape.
According to the order of participants’ attendance and
patch code, a box of patch was dispensed from small to large
numbers, which remained unchanged throughout the entire
trial. Participants were required to cover the left or right
index knee each day at bed time and remove 8 hours after
application in the morning (not to exceed 12 hours) with a
period of 7 days, which is similar with precious experimental
and trial studies [9, 11, 19]. The VAS and time of patch
application and removal were recorded daily in a diary for
compliance purpose.
Participants were encouraged to maintain their regular
activities and medications, including drugs of hypertension,
diabetes and other conditions, but not attending physical
therapy for knee OA other than using new analgesic. No
rescue medication was provided throughout the trial, but
patients have been fully informed to have the right to
withdraw at any time when they feel unbearable symptoms
of disease.
2.4. Outcome Measures. The primary eﬃcacy measure used
a VAS (score range 0–100mm) walking on ﬂat surface to
assess the change from baseline to day 1 and day 7 in
the patient’s assessment of pain score. Secondary outcome
measures were (1) patient global assessment of the change in
Western Ontario and McMaster Universities Osteoarthritis
Index(WOMAC,Likertscaleversion;scorerange0–96)[20].
The total WOMAC score is a summation of the scores for
each individual domain (pain (score range 0–20), stiﬀness
(score range 0–8), and physical function (score range 0–68));
(2) WOMAC pain, stiﬀness, and physical function subscales;
(3) subscale of investigator assessment knee OA condition
measured by TCM Syndrome Questionnaire (TCMSQ; score
range 0–24) (Table 1)[ 21]. Given the reason that Chinese
herbal medicine is applied under the principle of syndrome
diﬀerentiation according to TCM philosophy, TCMSQ is
used as an endpoint in this trial with higher scores indicating
more severe syndrome. Adherence and occurrence of AEs
were also assessed.
2.5. Safety Assessments. All patients were screened clinically,
biochemically, and by 12-lead electrocardiogram (ECG) for
any sign of conditions on day 0 and day 7 and repeated
if necessary. Vital signs were monitored, using a standard
adverse-event case report form at each visit. This form
included a description of all undesirable experiences, such as
(1) symptoms of skin itching, rash, blisters and skin damage;
(2) local pain and discomfort; (3) emergency situations
such as fracture or joint ﬂoating body; (4) abnormality
of kidney and liver functional tests. For all AEs linked to
patches, actions taken would be recorded and followed until
resolution of the event throughout the study.
2.6. Sample Size. We determined the sample size based on
previous data that the eﬃcacy of FNZG, SJG, and placebo
patch was 59.6%, 33.1%, and 10%, respectively [11, 13].
According to the 2:2:1 ratio, we estimated that FNZG (n =
52),SJG(n = 52),andplacebopatch(n = 26)weresuﬃcient
to give 0.8 power at 0.05 alpha level. Allowing for dropout,
150 participants were included.
2.7. Randomization and Blinding. Participants were ran-
domly and blindly assigned to FNZG group (n = 60), SJG
group (n = 60), or placebo group (n = 30) by the Evidence-
Based Medicine Center of Beijing University of Chinese
Medicine. The investigators, the subjects, those evaluating
outcomes,dataentrypersonnel,andstatisticianwereblinded
to treatment allocations.
2.8. Data Analysis. Data was managed through the online
facility established by the Evidence-Based Medicine Cen-
ter of Beijing University of Chinese Medicine (http://202
.204.46.209/cw/) and was analyzed on the full analysis set
(FAS) with the intent-to-treat principle, the per-protocol set
(PPS) for adherence, and safety set (SS) for adverse events.4 Evidence-Based Complementary and Alternative Medicine
Excluded (n = 31)
Not meeting including criteria (n = 16)
Scheduling conﬂicts (n = 5)
No interest n = 4)
Arranging diﬃculties (n = 4)
Physically unable to participate (n = 2)
Randomized (n = 150)
Assigned to the FNZG group
(n = 60)
Assigned to the SJP group
(n = 60)
Assigned to the placebo group
(n = 30)
Assessed for eligibility (n = 181)
Declined to participate
after assignment (n = 1)
Completed the 1-day
evaluation (n = 60)
Completed the 1-day
evaluation (n = 59)
Completed the 1-day
evaluation (n = 30)
Completed the 7-day
evaluation (n = 56)
Completed the 7-day
evaluation (n = 58)
Completed the 7-day
evaluation (n = 30)
Lost to follow up (n = 4)
Discontinued
intervention (n = 0)
Lost to follow up (n = 1)
Discontinued
intervention (n = 0)
Lost to follow up (n = 0)
Discontinued
intervention (n = 0)
(
Figure 1:Flowdiagramofthetrialprogressaboutenrollment,randomization,intervention,andcompletionof1-dayand7-dayevaluations.
Data for participants who lost to followup was estimated
using the last-observation-carried-forward (LOCF) method
fortheprimaryoutcomemeasure.Wecomparedthreegroup
changes from pre- and postscores with one-factor analysis
of variance (ANOVA). We evaluated for potential eﬀects of
confounding or interaction with treatment by covariates,
including age, sex, body mass index (BMI), disease duration,
and knee pain. Results are shown with 95% conﬁdence
interval (95% CI). All the statistical tests were used two sided
and set at the 5% level. Statistical analysis was performed
using SPSS version 16.0.
3. Results
3.1. Participants. Between June 2010 and January 2011, we
screened 181 patients with painful knee OA by telephone
and interview. 31 patients were excluded for various reasons,
and 150 qualiﬁed participants were randomly assigned to
FNZG group, SJG group, or placebo group, but one person
declined to participate after assignment, the speciﬁc reason
was unknown (Figure 1).
3.2. Baseline Characteristics of the Patients. The race of sub-
jects was Han Chinese, and the majority of them had greater
thanorequaltojuniorschooleducation.Table 2 summarizes
the main baseline characteristics of the 149 patients based
on FAS. Participants had a mean age of 59.3 years, and 91%
(136) were women. On average, participants had 4.4 years of
knee pain and BMI of 23.5kg/m2. At baseline, the demo-
graphic and clinical characteristics were reasonably well
balanced among the 3 groups except duration of knee pain
(P = 0.046), and there was also somewhat diﬀerence about
greater knee OA severity in the placebo group (Table 2).
3.3. Primary Outcome Measure. All three groups improved
with respect to a decrease from baseline to day 1 and day 7
in the VAS score. Similar improvements from baseline were
observed at day 1. Improvements from baseline were the
greatest in FNZG group and the smallest in SJG group at day
7. However, the diﬀerence between placebo (−17.68 points,
[95% CI, −22.16 to −13.21]) and FNZG (−19.02 points,
[95% CI, −23.23 to −14.81]; P = 0.858) as well as diﬀerence
between placebo and SJG (−16.04 points, [95% CI, −19.30
to −12.79]; P = 0.789) were not statistically signiﬁcant
(Table 3; Figure 2).
3.4.SecondaryOutcomeMeasures. Improvementsfrombase-
line to day 7 in the 3 WOMAC domains and total score
were seen in three groups. As compared with the changes ofEvidence-Based Complementary and Alternative Medicine 5
Table 2: Baseline characteristics of the study participants.
Variable Placebo (n = 30) FNZG (n = 60) SIG (n = 59) Total (n = 149)
Demographics
Han Chinese, no.(%) 30 (100) 60 (100) 59 (100) 149 (100)
Women, no.(%) 27 (90) 53 (88) 56 (95) 136 (91)
Age, years 60.4 ±8.05 8 .5 ±7.75 9 .6 ±6.1 59.3 ±7.1
Body mass index, kg/m2 23.4 ±2.72 3 .5 ±3.12 3 .7 ±2.72 3 .5 ±2.9
Disease condition
Duration of knee pain (on
study knee), years∗ 4.6 ±3.05 .1 ±4.13 .5 ±3.0 4.4 ±3.5
Patient VAS (study knee;
range 0–100mm) 53.3 ±15.25 1 .7 ±15.05 2 .5 ±14.7 52.3 ±14.8
WOMAC pain (range
0–20) 10.6 ±4.69 .2 ±4.39 .3 ±3.6 9.5 ±4.1
WOMAC stiﬀness (range
0–8) 3.6 ±1.93 .3 ±1.93 .4 ±1.9 3.4 ±1.9
WOMAC physical function
(range 0–68) 28.3 ±16.02 3 .9 ±14.62 5 .9 ±13.8 25.5 ±14.6
WOMAC total score (range
0–96) 42.5 ±22.03 6 .3 ±20.13 8 .5 ±18.23 8 .4 ±19.8
Investigator TCMSQ
subscale
Swelling (range 0–6) 2.7 ±1.72 .47 ±1.12 .14 ±1.4 2.4 ±1.3
Range of motion (range
0–6) 2.8 ±1.12 .87 ±1.12 .78 ±1.3 2.8 ±1.2
Fatigue in the region of
waist and knee muscles
(range 0–6)
3.5 ±1.53 .40 ±1.23 .22 ±1.3 3.4 ±1.3
Fear of coldness (range
0–6) 3.9 ±1.33 .92 ±1.43 .83 ±1.43 .9 ±1.4
Self-reported
comorbidities, no. (%)
Heart disease 0 (0) 3 (5) 1 (2) 4( 3 )
Hypertension 6 (20) 9 (15) 9 (15) 24 (16)
Diabetes 1 (3) 3 (5) 2 (3) 6 (4)
Valuesarethemean±SDorthenumber(percentage).Pvalueswerecalculatedbyone-factoranalysisofvariance(ANOVA).VAS:visualanalogscale;WOMAC:
Western Ontario and McMaster Universities Osteoarthritis Index; TCMSQ: Traditional Chinese Medicine Syndrome Questionnaire. ∗P = 0.046.
Table 3: Changes in primary outcome.
Variable Placebo (n = 30) FNZG (n = 60) SIG (n = 59)
Patient VAS (range
0–100mm)
Day 1 46.73 (40.97, 52.49) 45.72 (41.50, 49.94) 46.39 (42.73, 50.05)
Improvement from baseline −6.58 (−9.41,−3.76) −6.05 (−8.07, −4.03) −6.09 (−7.60, −4.58)
P value 0.909 0.919
Day 7 35.63 (28.94, 42.33) 34.19 (29.58, 38.80) 36.71 (33.12, 40.29)
Improvement from baseline −17.68 (−22.16, −13.21) −19.02 (−23.23, −14.81) −16.04 (−19.30, −12.79)
P value 0.858 0.789
Values are the mean (95% conﬁdence interval). P values were calculated by one-factor analysis of variance (ANOVA). VAS: visual analog scale.6 Evidence-Based Complementary and Alternative Medicine
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Figure 2: Mean changes of VAS score by treatment group during
the 7-day intervention period.
placebo and FNZG group, SJG group had greater improve-
ments in the scores for 3 WOMAC domains and total, but no
signiﬁcant diﬀerences were documented (Table 4).
Notably, FNZG grouphad a signiﬁcantlygreaterdecrease
in the item of fear of coldness as assessed by TCMSQ than
that in placebo group (−0.89 points, [95% CI, −1.23 to
−0.56] versus −0.29 points, [95% CI, −0.56 to −0.01]; P =
0.029), but SJG group did not reach a signiﬁcant reduction
(−0.69 points, [95% CI, −0.96 to −0.42]; P = 0.172).
All treatment eﬀects remained unchanged after adjusting
fordurationofkneepain,andnointeractionswithtreatment
were noted.
3.5. Adherence and Adverse Events. The rate of attendance
was 93%, 97%, and 100%, respectively, for FNZG, SJG and
placebo at the 7-day followup (Table 5). 1 person withdrew
from the study by 1 day and 6 persons by 7 days. 5 patients in
FNZG and 3 in SJG group missed some outcomes visits but
completed other followup evaluations.
The most common AEs of FNZG and SJG were rash,
itching, slightly damaged skin, or erythema in 7% of
participants based on SS. These symptoms disappeared
within 1 day to 3 days after discontinuation. One participant
in the FNZG group reported an increase in knee pain and
swelling (urticaria) after three-day usage. This was resolved
by discontinuation and giving anther kind of herbal patch
(Morengao) and taking Loxoprofen sodium tablet 60mg
immediately (Daiichi Sankyo Pharmaceutical (Shanghai)
Co., Ltd.). No server AEs were reported during the study.
4. Discussion
Our randomized, double-blind, placebo-controlled study
revealed that Traditional Chinese herbal patch FNZG might
be a useful therapy for knee OA in improving symptom of
fearofcoldnessasmeasuredbyTCMSQat7days.Noserious
AEs were reported in the study participants, indicating that
it may be a safe treatment for knee OA.
Severalstudieslackingplacebocontrolhaveevaluatedthe
eﬃcacy and safety of FNZG or SJG in the management of
knee pain [7–12] and TCM syndrome [13, 17]. One also
showed that FNZG was eﬀective as diclofenac cream [22].
Furthermore, AEs of FNZG or SJG including rash, itching,
slightly damaged skin, or erythema were also reported in
previous trials [8, 9, 11, 17, 22], but no allergic purpura of
FNZGwasfound[16].WithdrawalofFNZGparticipantswas
smaller than our trial (2/85 versus 4/60) [9].
According to features of knee OA, we chose two widely
applied patches, FNZG and SJG, to rigorously evaluate their
eﬃcacy and safety. Our outcome measures capture both
knee OA symptoms and the whole body situation. VAS is
a simple and frequently used method for the assessment
of variations in intensity of pain. In clinical practice, the
pain relief is often considered as a measure of the eﬃcacy
of treatment [23]. WOMAC is a widely used outcome
measure for OA treatments and is a validated scale to
assess OA pain, stiﬀness, and physical function [24, 25].
WOMAC is detailed in the description of local symptoms
of OA, whereas TCMSQ includes whole body’s assessment
in diﬀerent phases of OA. TCM syndrome is diﬀerent from
the disease name; it may not only include local symptoms
which are part of the disease but also symptoms from
the whole body situation [6]. Therefore, TCMSQ could
provide complementary information on outcome measures
and represent clinically meaningful eﬀects that were usually
neglected by conventional scales. Given this consideration,
swelling, range of motion, muscles fatigue, and fear of
coldness, as alternative endpoints, could be concerned in the
future study if available.
Although biological mechanism of Traditional Chinese
herbal patches in improving the clinical consequence of
knee OA is unclear, its analgesic and improvement of
cold-dampness evil components likely play an important
role. First, herbal patches may act as the kneepad. It has
been shown to have slight ﬁxation eﬀect and could help
patients overcome fear of pain as tape [26, 27]. Second,
since TCM believes that disease is linked with the aging
and feebleness, long-term strain, invasion of wind, cold,
or dampness evil [12], herbal patches could treat local
and even systemic conditions through the way of dispelling
cold evil, removing dampness evil, activating the blood,
and resolving stasis [28]. Third, it has a signiﬁcant anal-
gesic and anti-inﬂammatory eﬀect on local microcircula-
tion [29]. Some experimental data suggested that blood
levels of prostaglandin E2 (PGE2), interleukin-1 (IL-1) and
interleukin-6 (IL-6), were decreased, while β-endorphin (β-
EP)wasincreasedinpatientswithkneeOAafterusingFNZG
[30, 31]. Furthermore, it may have a potential inﬂuence on
neurochemical and immune system, thus improving TCM
syndrome in the whole body situation.
Our study had some limitations. The biggest limitation
was the relatively short-term. It should be noted that our
primary aim was to assess the eﬀectiveness and safety of
FNZG and SJG for painful knee OA for 7 days, and we
determined the similar intervention period on published
data [9, 11, 19]. Although OA is a chronic and degenerative
disease, extension of pain always has ﬂuctuation over the
course; that is, one-week period could be in line with
acute OA-pain ﬂare episodes. This treatment period isEvidence-Based Complementary and Alternative Medicine 7
Table 4: Changes in secondary outcomes.
Variable Placebo (n = 30) FNZG (n = 60) SIG (n = 59)
WOMAC: Pain (range 0–20)
Day 7 8.59 (6.92, 10.26) 7.45 (6.34, 8.56) 6.79 (5.91, 7.68)
Improvement from baseline −1.97 (−2.50, −1.43) −2.02 (−2.57, −1.47) −2.52 (−3.02, −2.02)
P value 0.988 0.310
Stiﬀness (range 0–8)
Day 7 2.97 (2.22, 3.72) 2.55 (2.06, 3.05) 2.60 (2.19, 3.02)
Improvement from baseline −0.66 (−1.00, −0.31) −0.77 (−0.99, −0.55) -0.78 (−1.10, −0.45)
P value 0.827 0.804
Physical function (range 0–68)
Day 7 22.38 (16.31, 28.45) 19.77 (16.03, 23.51) 19.41 (16.17, 22.66)
Improvement from baseline −6.10 (−8.34, −3.87) −5.04 (−6.21, −3.86) −6.71 (−8.24,−5.14)
P value 0.564 0.820
Total score (score 0–96)
Day 7 33.93 (25.58, 42.28) 29.71 (24.52, 34.93) 28.81 (24.48, 33.14)
Improvement from baseline −8.72 (−11.46, −5.99) −7.87 (−9.50, −6.26) −10.00 (−12.08, −7.92)
P value 0.800 0.616
Investigator TCMSQ subscaleSwelling (range 0–6)
Day 7 2.21 (1.73,2.70) 1.71 (1.50,2.07) 1.62 (1.33,1.91)
Improvement from baseline −0.50 (−0.84, −0.16) −0.71 (−1.01, −0.42) −0.51 (−0.84, −0.20)
P value 0.587 0.996
Range of motion (range 0–6)
Day 7 2.29 (1.78,2.79) 2.04 (1.74,2.33) 2.14 (1.84,2.43)
Improvement from baseline −0.50 (−0.90, −0.10) −0.89 (−1.21, −0.57) −0.66 (−0.90, −0.41)
P value 0.186 0.727
Fatigue in the region of waist and knee muscles
(range 0–6)
Day 7 3.00 (2.46,3.54) 2.89 (2.57,3.21) 2.55 (2.28,2.83)
Improvement from baseline −0.57(−0.99, −0.16) −0.46(−0.79, −0.14) −0.66 (−0.94, −0.37)
P value 0.870 0.917
Fear of coldness (range 0–6)
Day 7 3.57 (3.04,4.10) 3.04 (2.63,3.44) 3.14 (2.75,3.52)
Improvement from baseline −0.29 (−0.56,−0.01) −0.89 (−1.23,−0.56) −0.69 (−0.96,−0.42)
P value 0.029 0.172
Values are the mean (95% conﬁdence interval). P values were calculated by one-factor analysis of variance (ANOVA). WOMAC: Western Ontario and
McMaster Universities Osteoarthritis Index; TCMSQ: Traditional Chinese Medicine Syndrome Questionnaire.
Table 5: Summary of adherence and adverse events (AEs).
Variable Placebo FNZG SIG Total
Adherence no. (%)
Day 1 30 (100) 60 (100) 59 (98) 149 (99)
Day 7 30 (100) 56(93) 58(97) 144 (96)
All AEs∗
Patch site reaction 0 (0) 4 (7) 4 (7) 8 (5)
Leading to study withdrawal 0 (0) 1 (2) 0 (0) 1 (1)
Resulting in hospitalization
and death 0 (0) 0 (0) 0 (0) 0 (0)
Values are the number (percentage). ∗Based on 149 patients (60 FNZG, 59 SJG, 30 placebo).8 Evidence-Based Complementary and Alternative Medicine
also consistent with clinical practice, as patients’ adherence
would be extremely poor if pain could not be satisfactorily
controlled by topical treatment alone within a short period.
Sinceweonlyrecruitedpatientswithpainintensityof20mm
or more on VAS, participants may have equal and higher
responding to treatment than those without such restriction.
Similarly, many OA trials have set “ﬂare” group in which
participants must have sensitive respond to treatment, such
as symptoms getting back easily while stopping medication
[32]. Future studies should conduct long-term followup
to verify whether the beneﬁts are maintained. Another
limitation was the smaller response rate to detect the desired
signiﬁcance level. It was not due to sample size alone which
was rigorously calculated, rather, it could be explained by
the fact that the cohort we recruited with relatively mild
degree of knee pain at baseline (VAS = 52.3mm) might
be insensitive in identifying improvement compared with
high-response populations. We had attempted to analyze
data by stratiﬁcation of knee pain, but the result still
unchanged, indicating a really no diﬀerence in this time
interval. In addition, although VAS is a validated measure
for pain, its estimate performed by patients with chronic
pain may be imprecision [23, 33]. Therefore, both objective
and subjective status of knee pain assessed separately by
participant and investigator could be considered in future
work.
5. Conclusion
Our preliminary ﬁndings indicate that Traditional Chinese
herbal patches FNZG or SJG may have limited eﬀect to
improve knee pain, stiﬀness, and physical function of knee
OA in a short-term treatment. The local adverse events
of rash, itching, erythema, and slightly damaged skin were
reported in few people. However, patients receiving FNZG
could get signiﬁcant improvement in symptom of fear of
coldness as measured by TCMSQ.
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